A novel arginase inhibitor derived from scutellavia indica restored endothelial function in apoe-null mice fed a high-cholesterol diet

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 1, 2015, Pages 57-65

  Hwang, Hye Mi ^a   Lee, Jeong Hyung ^a   Min, Byung Sun ^b   Jeon, Byeong Hwa ^c   Hoe, Kwang Lae ^d   Kim, Young Myeong ^a   Ryoo, Sungwoo ^a  

^a Kangwon National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chungnam National University   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5,2',5' TRIHYDROXY 7,8 DIMETHOXYFLAVANONE; ACETYLCHOLINE; ARGINASE; ARGINASE 1; ARGINASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVANONE DERIVATIVE; HYDROLASE INHIBITOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; SERINE; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; ARG1 PROTEIN, MOUSE; ARG2 PROTEIN, MOUSE; CHOLESTEROL INTAKE; DIOCLEIN; ENZYME INHIBITOR; METHANOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IC50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; SCUTELLARIA; SCUTELLARIA INDICA; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; VASOCONSTRICTION; VASODILATATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; CHOLESTEROL INTAKE; CYTOLOGY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; GENE DELETION; GENETICS; HYPERLIPIDEMIAS; ISOLATION AND PURIFICATION; LIPID DIET; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; APOLIPOPROTEINS E; ARGINASE; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FLAVANONES; GENE DELETION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERLIPIDEMIAS; MALE; METHANOL; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; REACTIVE OXYGEN SPECIES; SCUTELLARIA; SIGNAL TRANSDUCTION;

EID: 85047700264     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.224592     Document Type: Article

References (40)

1. Ansel GM and Lumsden AB (2009) Evolving modalities for femoropopliteal interventions. J Endovascular Ther 16:II82-II97.
2. Barbato JE, Kibbe MR, and Tzeng E (2003) The emerging role of gene therapy in the treatment of cardiovascular diseases. Crit Rev Clin Lab Sci 40:499-545.
3. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, and Champion HC, et al. (2003) Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108:2000-2006.
4. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, and Cannon RO, 3rd (2000) Oral L-arginine in patients with coronary artery disease on medical management. Circulation 101:2160-2164.
5. Böger RH (2008) L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care 11:55-61.
6. Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, and Frölich JC (1995) Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117:273-284.
7. Chang CI, Liao JC, and Kuo L (1998) Arginase modulates nitric oxide production in activated macrophages. Am J Physiol 274:H342-H348.
8. Christianson DW (2005) Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc Chem Res 38:191-201.
9. Collado B, Sánchez-Chapado M, Prieto JC, and Carmena MJ (2006) Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol Cell Endocrinol 249:116-122.
10. Dudek D, Legutko J, Heba G, Bartus S, Partyka L, Huk I, Dembinska-Kiec A, Kaluza GL, and Dubiel JS (2004) L-arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study. Am Heart J 147:E12.
11. Griffiths MJ and Evans TW (2005) Inhaled nitric oxide therapy in adults. N Engl J Med 353:2683-2695.
12. Haraguchi Y, Takiguchi M, Amaya Y, Kawamoto S, Matsuda I, and Mori M (1987) Molecular cloning and nucleotide sequence of cDNA for human liver arginase. Proc Natl Acad Sci USA 84:412-415.
13. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N and Kuo L (2003) Ischemiareperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 17:2328-2330.
14. Ichinose F, Roberts Jr JD, and Zapol WM (2004) Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 109:3106-3111.
15. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, and del Soldato P (2001) Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 98:4202-4208.
16. Johnson FK, Johnson RA, Peyton KJ, and Durante W (2005) Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 288:R1057-R1062.
17. Jung C, Gonon AT, Sjöquist PO, Lundberg JO, and Pernow J (2010) Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 85:147-154.
18. Kawashima S (2004) The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. J Endothelial Cell Res 11:99-107.
19. Kibbe MR and Tzeng E (2000) Nitric oxide synthase gene therapy in vascular pathology. Semin Perinatol 24:51-54.
20. Kim SW, Cuong TD, Hung TM, Ryoo S, Lee JH, and Min BS (2013) Arginase II inhibitory activity of flavonoid compounds from Scutellaria indica. Arch Pharm Res 36:922-926.
21. Li H and Förstermann U (2009) Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des 15:3133-3145.
22. Li H, Meininger CJ, Hawker Jr JR, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris Jr SM, and Wu G (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280:E75-E82.
23. Louis CA, Reichner JS, Henry Jr WL, Mastrofrancesco B, Gotoh T, Mori M, and Albina JE (1998) Distinct arginase isoforms expressed in primary and transformed macrophages: regulation by oxygen tension. Am J Physiol 274:R775-R782.
24. Maarsingh H, Zaagsma J, and Meurs H (2009) Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol 158:652-664.
25. Modolell M, Corraliza IM, Link F, Soler G, and Eichmann K (1995) Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrowderived macrophages by TH1 and TH2 cytokines. Eur J Immunol 25:1101-1104.
26. Morris Jr SM, Bhamidipati D, and Kepka-Lenhart D (1997) Human type II arginase: sequence analysis and tissue-specific expression. Gene 193:157-161.
27. Morris Jr SM, Kepka-Lenhart D, and Chen LC (1998) Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 275:E740-E747.
28. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, and Yoshida Y, et al. (2002) Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 110:331-340.
29. Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM, Wang H, Tulis DA, and Durante W (2009) Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol 29:488-494.
30. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, Lim HK, Sohi J, Santhanam L, and Soucy K, et al. (2008) Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 102:923-932.
31. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D, Shoukas A, Romer LH, and Berkowitz DE (2006) Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 99:951-960.
32. Santhanam L, Lim HK, Lim HK, Miriel V, Brown T, Patel M, Balanson S, Ryoo S, Anderson M, and Irani K, et al. (2007) Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 101:692-702.
33. Shi W, Wang X, Shih DM, Laubach VE, Navab M, and Lusis AJ (2002) Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 105:2078-2082.
34. Steppan J, Nyhan D, and Berkowitz DE (2013) Development of novel arginase inhibitors for therapy of endothelial dysfunction. Front Immunol 4:278.
35. Walker HA, McGing E, Fisher I, Böger RH, Bode-Böger SM, Jackson G, Ritter JM, and Chowienczyk PJ (2001) Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 38:499-505.
36. Wilson AM, Harada R, Nair N, Balasubramanian N, and Cooke JP (2007) L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116:188-195.
37. Woo A, Shin W, Cuong TD, Min B, Lee JH, Jeon BH, and Ryoo S (2013) Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet. Int J Mol Med 31:803-810.
38. Yoon J, Park M, Lee Jh, Min BS, and Ryoo S (2014) Endothelial nitric oxide synthase activation through obacunone-dependent arginase inhibition restored impaired endothelial function in ApoE-null mice. Vascul Pharmacol 60:102-109.
39. Yu Y, Rajapakse AG, Montani JP, Yang Z, and Ming XF (2014) p38 mitogen-activated protein kinase is involved in arginase-II-mediated eNOS-uncoupling in obesity. Cardiovasc Diabetol 13:113.
40. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, and Kuo L (2004) Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44:935-943.